ticlopidine has been researched along with Pulmonary Fibrosis in 3 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A comparative clinical study examined the preventive effect of ticlopidine hydrochloride (hereinafter referred to as ticlopidine, anti-platelet drug) on Peplomycin sulfate (hereinafter referred to as Peplomycin) pulmonary fibrosis." | 7.68 | [Preventive effect of ticlopidine on peplomycin pulmonary fibrosis]. ( Fukuda, H; Negishi, T; Oowada, F; Saito, H; Saito, T; Tari, K; Tsujii, T; Yamada, T; Yonese, J; Yoshida, K, 1990) |
| "A comparative clinical study examined the preventive effect of ticlopidine hydrochloride (hereinafter referred to as ticlopidine, anti-platelet drug) on Peplomycin sulfate (hereinafter referred to as Peplomycin) pulmonary fibrosis." | 3.68 | [Preventive effect of ticlopidine on peplomycin pulmonary fibrosis]. ( Fukuda, H; Negishi, T; Oowada, F; Saito, H; Saito, T; Tari, K; Tsujii, T; Yamada, T; Yonese, J; Yoshida, K, 1990) |
| " Combination therapy of anti-platelet aggregating agents such as phthalazinol, dipyridamole, ticlopidine and indomethacin suppressed these toxic changes." | 1.28 | [Effects of anti-platelet aggregating agents on peplomycin induced pulmonary toxicity in mice]. ( Ekimoto, H; Ito, J; Okada, M; Takahashi, K, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vasil'ev, SN | 1 |
| Stepanian, IE | 1 |
| Kaminskaia, GO | 1 |
| Serebrianaia, BA | 1 |
| Shmelev, EI | 1 |
| Tari, K | 1 |
| Tsujii, T | 1 |
| Yonese, J | 1 |
| Saito, T | 1 |
| Oowada, F | 1 |
| Fukuda, H | 1 |
| Negishi, T | 1 |
| Yamada, T | 1 |
| Saito, H | 1 |
| Yoshida, K | 1 |
| Okada, M | 1 |
| Ekimoto, H | 1 |
| Ito, J | 1 |
| Takahashi, K | 1 |
3 other studies available for ticlopidine and Pulmonary Fibrosis
| Article | Year |
|---|---|
[The hemostatic system and correction of its impairments, by using the disaggregatory agent ticlopidine and low-molecular-weight heparin in patients with idiopathic fibrosing alveolitis].
Topics: Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemodynamics; Heparin, Low-Molecular-Weight; | 2005 |
[Preventive effect of ticlopidine on peplomycin pulmonary fibrosis].
Topics: Bleomycin; Humans; Infusion Pumps; Peplomycin; Pulmonary Fibrosis; Ticlopidine; Urologic Neoplasms | 1990 |
[Effects of anti-platelet aggregating agents on peplomycin induced pulmonary toxicity in mice].
Topics: Animals; Bleomycin; Lung Diseases; Male; Mice; Mice, Inbred ICR; Peplomycin; Platelet Aggregation In | 1989 |